XML 106 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Shareholders' Equity
 9 Months Ended
Sep. 30, 2014
Stockholders' Equity Note [Abstract]  
Shareholders' Equity
NOTE 14. SHAREHOLDERS’ EQUITY
Changes in Shareholders' Equity
The following table displays a reconciliation of our beginning and ending balances in shareholders' equity for the nine months ended September 30, 2014 (in thousands):
 
Attributable to: 
 
Endo
International plc
 
Noncontrolling
interests  
 
Total
Shareholders’
Equity
Shareholders’ equity at January 1, 2014
$
526,018

 
$
59,198

 
$
585,216

Net (loss) income
(667,836
)
 
2,895

 
(664,941
)
Other comprehensive (loss) income
(39,171
)
 
363

 
(38,808
)
Compensation related to share-based awards
23,150

 
—

 
23,150

Tax withholding for restricted shares
(23,920
)
 
—

 
(23,920
)
Exercise of options
36,124

 
—

 
36,124

Distributions to noncontrolling interests
—

 
(6,144
)
 
(6,144
)
Buy-out of noncontrolling interests, net of contributions
—

 
(82
)
 
(82
)
Addition of Paladin noncontrolling interests due to acquisition
—

 
40,600

 
40,600

Removal of HealthTronics, Inc. noncontrolling interests due to disposition
—

 
(57,359
)
 
(57,359
)
Ordinary shares issued in connection with the Paladin acquisition
2,844,279

 
—

 
2,844,279

Repurchase of convertible senior subordinated notes due 2015
(309,829
)
 
—

 
(309,829
)
Settlement of common stock warrants
(284,454
)
 
—

 
(284,454
)
Settlement of the hedge on convertible senior subordinated notes due 2015
356,265

 
—

 
356,265

Other
30,095

 
—

 
30,095

Shareholders’ equity at September 30, 2014
$
2,490,721

 
$
39,471

 
$
2,530,192


As part of the reorganization upon consummation of the Paladin acquisition, EHSI Common stock and Treasury stock in the amounts of $1.5 million and $763.1 million, respectively, were retired and reclassified into Additional paid-in capital.
The following table displays a reconciliation of our beginning and ending balances in shareholders' equity for the nine months ended September 30, 2013 (in thousands):
 
Attributable to: 
 
Endo
International plc
 
Noncontrolling
interests  
 
Total
Shareholders’
Equity
Shareholders’ equity at January 1, 2013
$
1,072,856

 
$
60,350

 
$
1,133,206

Net income
90,571

 
38,758

 
129,329

Other comprehensive income
863

 
—

 
863

Compensation related to share-based awards
31,258

 
—

 
31,258

Tax withholding for restricted shares
(8,284
)
 
—

 
(8,284
)
Exercise of options
83,743

 
—

 
83,743

Ordinary shares issued from treasury, net of ordinary shares purchased
4,117

 
—

 
4,117

Distributions to noncontrolling interests
—

 
(36,709
)
 
(36,709
)
Buy-out of noncontrolling interests, net of contributions
—

 
(1,913
)
 
(1,913
)
Other
1,754

 
—

 
1,754

Shareholders’ equity at September 30, 2013
$
1,276,878

 
$
60,486

 
$
1,337,364


Share-Based Compensation
The Company recognized share-based compensation expense of $8.8 million and $23.2 million during the three and nine months ended September 30, 2014, respectively, compared to $8.5 million and $31.3 million during the three and nine months ended September 30, 2013, respectively. As of September 30, 2014, the total remaining unrecognized compensation cost related to all non-vested share-based compensation awards and options amounted to $59.4 million. As of September 30, 2014, the weighted average remaining requisite service period was 2.0 years for non-vested stock options, 0.5 years for non-vested restricted stock awards and 2.1 years for non-vested restricted stock units.